Synthesis and biological study of a new series of 4′- demethylepipodophyllotoxin derivatives

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 593-603

  Duca, Maria ^a,b   Guianvarc'h, Dominique ^a,d   Meresse, Philippe ^b   Bertounesque, Emmanuel ^b   Dauzonne, Daniel ^b   Kraus Berthier, Laurence ^c   Thirot, Sylvie ^b   Léonce, Stéphane ^c   Pierré, Alain ^c   Pfeiffer, Bruno ^c   Renard, Pierre ^c   Arimondo, Paola B ^a   Monneret, Claude ^b  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b CNRS   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXO 13 DEOXO 4' NOREPIPODOPHYLLOTOXIN 4 [N [2 (N',N' DIMETHYLAMINOETHYL)]]CARBAMATE; 4' NOREPIPODOPHYLLOTOXIN 4 [N [2 (N',N' DIMETHYLAMINOETHYL)]]CARBAMATE; 4' NOREPIPODOPHYLLOTOXIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA P 388; LUNG CARCINOMA; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; LEUKEMIA P388; MICE; PODOPHYLLOTOXIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 19944430141     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0495733     Document Type: Article

References (35)

1. Belani, C. P.; Doyle, L. A.; Aisner, J. Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol 1994, 34 Suppl. S118-126.
2. Hande, K. R. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998, 34, 1514-1521.
3. Pommier, Y.; Fesen, M. R.; Goldwasser, F. Cancer Chemotherapy and Biotherapy: Principles and Practice; Chabner, B. A., Longo, D. L., Eds.; Lippincott-Raven Publishers: Philadelphia, PA, 1996; pp 435-461.
4. Bromberg, K. D.; Burgin, A. B.; Osheroff, N. A two-drug model for etoposide action against human topoisomerase IIα. J. Biol. Chem. 2003, 278, 7406-7412.
5. Fortune, J. M.; Osheroff, N. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 2000, 64, 221-253.
6. Osheroff, N. DNA topoisomerases. Biochim. Biophys. Acta 1998, 1400, 1-2.
7. Champoux, J. J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
8. Capranico, G.; Binaschi, M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta 1998, 1400, 185-194.
9. Burden, D. A.; Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 139-154.
10. Kobayashi, K.; Ratain, M. J. Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother. Pharmacol. 1994, 34 Suppl. S64-8.
11. Terada, T.; Fujimoto, K.; Nomura, M.; Yamashita, J.; Wierzba, K.; Yamazaki, R.; Shibata, J.; Sugimoto, Y.; Yamada, Y.; Kobunai, T.; et al. Synthesis and biological activity of 4-beta-alkyl derivatives containing hydroxy, amino, and amido groups of (4′-O-demethyl-4-desoxypodophyllotoxin as antitumor agents. J. Med. Chem. 1993, 36, 1689-1699.
12. Huang, T. S.; Lee, C. C.; Chao, Y.; Shu, C. H.; Chen, L. T.; Chen, L. L.; Chen, M. H.; Yuan, C. C.; Whang-Peng, J. A novel podophyllotoxin-derived compound GL-331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res. 1990, 16, 997-1002.
13. Utsugi, T.; Shibata, J.; Sugimoto, Y.; Aoyagi, K.; Wierzba, K.; Kobunai, T.; Terada, T.; Oh-hara, T.; Tsuruo, T.; Yamada, Y. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res. 1996, 56, 2809-2814.
14. Byl, J. A.; Cline, S. D.; Utsugi, T.; Kobunai, T.; Yamada, Y.; Osheroff, N. DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action. Biochemistry 2001, 40, 712-718.
15. Guianvarc'h, D.; Duca, M.; Boukarim, C.; Kraus-Berthier, L.; Leonce, S.; Pierré, A.; Pfeiffer, B.; Renard, P.; Arimondo, P.; Monneret, C.; Dauzonne, D. Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J. Med. Chem. 2004, 47, 2365-2374.
16. Daley, L.; Guminski, Y.; Demerseman, P.; Kruczynski, A.; Etievant, C.; Imbert, T.; Hill, B. T.; Monneret, C. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide and NK611. J. Med. Chem. 1998, 41, 4475-4485.
17. Zhang, Y.; Lee, K. H. Recent progress in the development of novel antitumor etoposide analogs. Chin. Pharm. J. 1994, 46, 319-369.
18. Dow, L.; Sinkule, J. A.; Look, A. T.; Horvath, A.; Evans W. E. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4′-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-β-D- glucopyranoside) and 4′-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene- β-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts. Cancer Res. 1983, 43, 5699-5706.
19. Meresse, P.; Magiatis, P., Bertounesque, E.; Monneret, C. Synthesis and antiproliferative activity of retroetoposide. Bioorg. Med. Chem. Lett. 2003, 13, 4107-4109.
20. Zhou, X. M.; Lee, K. J.; Cheng, J.; Wu, S. S.; Chen, H. X.; Guo, X.; Cheng, Y. C.; Lee, K. H. New γ-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II. J. Med. Chem. 1994, 37, 287-292.
21. The Sybyl program (version 6.0) is available from Tripos Associates, 1699 South Hanley Road, St. Louis, MO 63144. CS ChemBats3D Pro software is available from CambridgeSoft Corp., Cambridge, MA).
22. Kingma, P. S.; Burden, D. A.; Osheroff, N. Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance. Biochemistry 1999, 38, 3457-3461.
23. Leroy, D.; Kajava, A. V.; Frei, C.; Gasser, S. M. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 2001, 40, 1624-1634.
24. Damayanthi, Y.; Lown J. W. Podophyllotoxins: Current status and recent developments. Curr. Med. Chem. 1998, 5, 205-252.
25. Macdonald, T. L.; Lehnert, E. K.; Loper, J. T.; Chow, K.-C.; Ross, W. E. On the mechanism of interaction of DNA topoisomerase II with chemotherapeutic agents in DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991; pp 199-214.
26. Tepe, J. J.; Madalengoitia, J. DS.; Slunt, K. M.; Werbovetz, K. W.; Spoors, P. G.; Macdonald, T. L. Inhibition of DNA topoisomerase II by azaelliptitoxins functionnalized in the variable substituent domain. J. Med. Chem. 1996, 39, 2188-2196.
27. Xiao, Z.; Xiao, Y.-D.; Feng, J.; Golbraikh, A.; Tropsha, A.; Lee, K. H. Antitumor Agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR Method. J Med. Chem. 2002, 45, 2294-2309.
28. 2-GRS approach. J. Med. Chem. 1996, 39, 1383-1395.
29. Avison, A. W. D.; Morrison, A. L. Synthetic Analgesics. Part VIII. Further attempts to prepare 3-Phenylpiperidine derivatives. J. Chem. Soc. 1950, 1474-1477.
30. Leonce, S.; Anstett, M.; Combe-Perez, V.; Pierre, A. Flow cytometric evaluation of the cell cycle perturbations induced by S12363, a new vinca alkaloid derivative. Anti Cancer Drugs 1990, 1, 179-183.
31. Pierré, A.; Perez, V.; Leonce, S.; Boutin, J. A.; Saint-Dizier, D.; Hautefaye, P.; Lavielle, G.; Atassi, G. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. Cancer Chemother. Pharmacol. 1992, 29, 367-374.
32. Guilbaud, N.; Kraus-Berthier, L.; Saint-Dizier, D.; Rouillon, M. H.; Jan, M.; Burbridge, M.; Visalli, M.; Bisagni, E.; Pierré, A.; Atassi, G. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother. Pharmacol. 1996, 38, 513-521.
33. Kraus-Berthier, L.; Jan, M.; Guilbaud, N.; Naze, M.; Pierré, A.; Atassi, G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Cancer Res. 2000, 6, 297-304.
34. Workman, P.; Balmain, A.; Hickman, J. A.; McNally, N. J.; Rohas, A. M.; Mitchison, N. A.; Pierrepoint, C. G.; Raymond, R.; Rowlatt, C.; Stephens, T. C.; Wallace, J.; Straughan, D. W. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim. 1988, 22, 195-201.
35. Zavala, F.; Guenard, D.; Robin, J.-P.; Brown, E. Structure-Antitubulin activity relationships in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (±)-isodoxypodophyllotoxin. J. Med. Chem. 1980, 23, 546-549.